When Emma was diagnosed with triple-negative breast cancer, she didn't let it define her. There are so many ways cancer steals possibility, but at Gilead, we’re helping take it back.
GileadNews: We’re joining with Kite Pharma to announce the presentation of transformative cancer research at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.
“Living with primary biliary cholangitis (PBC) can be an isolating experience,” explains Dilek, a mother of two from Germany who suffers from the rare chronic liver disease.
Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that safeguard the planet.
At Gilead, we innovate for impact. This commitment helps us drive scientific solutions forward, reach more people in more places and protect the planet we all share.
Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential People in the World.
Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu – an online mapping tool that visualizes granular data
At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases. In this installment of The Centrifuge Sessions, See Phan, Vice President, Oncology Clinical Development
This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV.
We’re focused on driving innovation in virology, oncology and immunology – and that includes investing in world-class science to change the way cancer is treated.
Since the pledge, Gilead has continued its long history in supporting reducing deaths from VL and controlling other neglected tropical diseases such as cryptococcal meningitis in efforts to advance global health equity.
Dr. Shringar Rao’s inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
Claudia Hardy says she’s found her life’s mission. As director of Community Health Access and Relations for the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, she brings cancer resources and preventive care to communities.
Gilead Sciences, Inc. (Nasdaq: GILD) was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA).
Shortly after Sandra joined Gilead, this company ambition touched close to home. She worked on an acquisition that ended up being the backbone of Gilead’s work to develop a cure for hepatitis C.
Over the years, Gilead has thoughtfully and boldly focused on communities with the greatest unmet needs, and women and girls – in particular, Black women and girls – are always at the top of the list.
This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.
When Stacey Ma was a little girl, her dream was to work with patients as a doctor. “As it turns out, I became an engineer who makes medicine to help patients,” says Stacey, who joined Gilead last summer to lead the Pharmaceutical Development and Manufacturing (PDM) team
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...